Biotech & Health Tech
STAT+: Pharmalittle: We’re reading about India’s new manufacturing rules, clinical trials in China, and more
India proposed rules requiring regulators to immediately suspend manufacturing licenses for drugs that fail quality standards in government testing
India proposed rules requiring regulators to immediately suspend manufacturing licenses for drugs that fail quality standards in government testing
This is a summary of the story. Read the full article at Stat News (Biotech & Health Tech) ↗